Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03070301 · ClinicalTrials.gov registry record · Phase 2

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target

NCT03070301: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03070301 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03070301, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.

Primary Outcome

using RECIST v1.1

Interventions

  • DRUG everolimus
  • DRUG LEE011

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2017-02-27
Est. Completion 2024-01-31
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT03070301 record still lists

NCT03070301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 2 interventions - of which everolimus is the first listed.

NCT03070301 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03070301 about?

NCT03070301 is a clinical study titled "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors". The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.

What is the current status of trial NCT03070301?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-02-27. Estimated completion is 2024-01-31.

What interventions are being tested in trial NCT03070301?

The interventions under investigation include: everolimus (DRUG), LEE011 (DRUG).

Who is sponsoring clinical trial NCT03070301?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03070301's enrollment target sits among peer trials

21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03070301, the US trial registry maintained by the National Library of Medicine. NCT03070301 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.